Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Jubilant DraxImage Appoints New Member of its Executive team

April 2, 2013

Addition of Mr. Kevin Brooks strengthen further Jubilant DraxImage
expertise

MONTREAL, April 2, 2013 /PRNewswire/ – Jubilant DraxImage Inc.
(hereinafter “JDI”), a Jubilant Life Sciences Company, is pleased to
announce the appointment of Mr. Kevin Brooks in the role of Vice
President Sales, Marketing and Business Development with effect from
today.

With more than twenty years of progressive commercial experience in the
specialty pharmaceuticals and targeted medical device markets, Kevin
Brooks is a seasoned leader with a strong understanding of business and
global radiopharmaceutical market dynamics.  Martyn Coombs, President
of Jubilant DraxImage stated; “Kevin’s expertise in conceptualizing and
launching new products as well as rejuvenating mature product lines
will be a significant asset to Jubilant Draximage.”

Kevin joins Jubilant DraxImage from Nordion Inc., where he recently
served as Senior Vice President of Sales and Marketing and a member of
the Executive Management Team, responsible for the company’s Global
Sales, Marketing, Customer Service and Business Development functions. 
Prior to joining Nordion in July 2006, Kevin served as Global Marketing
Director Nuclear Cardiology at GE Healthcare, where he led marketing
and cross-functional brand team initiatives for Myoview, a SPECT
myocardial perfusion agent.  Earlier, he worked with Bracco Diagnostics
Inc., as Marketing Director Nuclear Medicine, responsible for the
company’s generic and branded radiopharmaceutical products, which
included Rb-82 generators, 99mTc-cold kits and I-131 radioiodine
therapy products.

He holds a Bachelor of Health Science from Gwynedd Mercy College
(Pennsylvania) and a Master of Business Administration from Temple
University (Philadelphia, PA) as well as being a former Nuclear
Medicine Technologist and Medical Sonographer.

About Jubilant DraxImage Inc.
Jubilant DraxImage Inc., a subsidiary of Jubilant Life Sciences,
develops, manufactures and markets diagnostic and therapeutic
radiopharmaceuticals for the global nuclear medicine marketplace.
Jubilant DraxImage Inc.’s mission is to be a leading global provider of
radiopharmaceuticals and value-added enabling technologies. Products
include a proprietary line of lyophilized Technetium-99m kits (MAA,
MDP, DTPA and Sestamibi). Jubilant DraxImage Inc. is also a leading
supplier of I-131 radiopharmaceuticals in North America, used for the
diagnosis and treatment of thyroid disorder and cancer. Jubilant
DraxImage Inc. products are exported worldwide, with regulatory
approvals in USA, South America, parts of Europe and South Asia. More
information about Jubilant DraxImage is available at www.draximage.com.

SOURCE Jubilant DraxImage Inc.


Source: PR Newswire